July 2, 2012 (Shareholders Foundation) -- An investigation on behalf of investors in Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) shares was announced concerning whether the offer to acquire Amylin Pharmaceuticals, Inc. at $31 per NASDAQ:AMLN shares and the takeover process are unfair to investors in NASDAQ:AMLN shares.

The investigation by a law firm concerns whether certain officers and directors of Amylin Pharmaceuticals, Inc. breached their fiduciary duties owed NASDAQ:AMLN investors in connection with the proposed acquisition.
On June 29, 2012, after the market closed, Bristol-Myers Squibb Company (NYSE: BMY) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

However, Shares of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) grew from as low as $6.05 in November 2008 to as high as $28.21 per share on May 29, 2012. In addition, at least one analyst has set the high target price for NASDAQ:AMLN shares at $32 per share.

Therefore the investigation for Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN investors concerns whether the proposed transaction is unfair to Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN stockholders. Specifically, the investigation focuses on whether the Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.